TRVI - Wutah pendapatan taun lumaku Trevi Therapeutics

Trevi Therapeutics (TRVI) price action is tied to the success of Haduvio and the prospects of an acquisition by a major player. The relative sales growth over a 12-month period compared to last year visualizes this trend, where 0.00 indicates the current level. The absence of stable cash flows makes the company dependent on external investments, yet steady demand for neurological drugs provides the asset with defensive qualities against global macroeconomic crises.
Trevi Corp (TRVI) - rincian metrik lan laporan keuangan

This indicator measures the revenue growth rate over the last twelve months, allowing investors to assess the fundamental stability of the business through the discounting of future cash flows. By analyzing the year-over-year (LTM) gross revenue trend, one can identify operational disruptions, which are critical for Trevi Therapeutics (TRVI) due to the binary risks of Haduvio trials and the high cash burn rate prior to FDA approval.